State Street’s VistaGen Therapeutics VTGN Stock Holding History
Bought
Maintained
Sold
Other funds holding VTGN
CC
IC
AI
LM
ACM
State Street's VTGN Position: Q2 2026 in Review
State Street held its VistaGen Therapeutics (VTGN) position steady in Q2 2026 at 121,114 shares worth $27.4K. The position accounts for ﹤0.01% of the portfolio, ranked #4193.
State Street first reported a position in VTGN in Q2 2021 and has held it in 21 quarters since. The position peaked at $21.5M in Q3 2021. 48 funds tracked by Wall St. Rank hold VTGN as of Q2 2026.
- State Street held 121,114 shares of VistaGen Therapeutics worth $27.4K as of Q2 2026.
- State Street left its VistaGen Therapeutics share count unchanged in Q2 2026.
- VistaGen Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #4193 holding.
- State Street first reported a position in VistaGen Therapeutics in Q2 2021 and has held it in 21 quarters since.
- State Street's VistaGen Therapeutics position peaked at $21.5M in Q3 2021.
- 48 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.